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Highlights 
• Visit-to-visit lipid variability is increasingly being linked to adverse outcomes. 
• Levels may depend on dosage and dosing schedule of lipid-lowering agents. 
• Genome-wide testing provides no evidence for effects of common variants. 
• Study heterogeneity and likely publication bias impede literary interpretation. 
• There exists ample room for phenotype harmonisation amongst studies.  
 
Abstract 
In recent years, visit-to-visit variability of serum lipids has been linked to both clinical outcomes and 
surrogate markers for vascular disease. In this article, we present an overview of the current evidence 
connecting this intra-individual variability to these outcome measures, discuss its interplay with lipid-
lowering treatment, and describe the literature regarding genetic factors of possible interest. In addition, 
we undertook an explorative genome-wide association analysis on visit-to-visit variability of LDL-C and 
HDL-C, examining additive effects in 2,530 participants from the placebo-arm of the PROSPER trial. 
While we identified suggestive associations (p<1x10-6) at 3 different loci (KIAA0391, ACCN1, DKK3), 
previously published data from the GWAS literature did not suggest plausible mechanistic pathways. 
Given the large degree of both clinical and methodological heterogeneity in the literature, additional 
research is needed to harmonize visit-to-visit variability parameters across studies and to definitively 
assess the possible role of (pharmaco)genetic factors. 
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Introduction 
There is a growing body of evidence showing that, in addition to average levels, fluctuations in various 
traditional risk factors may be of importance to cardiovascular risk assessment. For example, it is now 
well-established that higher intra-individual variability of blood pressure (BP)1-3 and lower variability in 
heart rate4, 5 associate with various adverse outcomes. However, lipid concentrations are also known to 
fluctuate substantially, even on a day-to-day basis.6, 7  
Modulated by a myriad of factors including biological, sampling, analytical, and clinical conditions,8 this 
measurement ‘noise’ may lead to uncertainty in clinical practice, making repeated lipid measurements 
necessary before determining that a patient is above a disease or risk threshold, or when evaluating the 
efficacy of lipid-level altering treatments.  
Recent evidence suggests that visit-to-visit variability of lipids may independently associate with adverse 
outcomes. Here, we present an overview of the current literature linking this intra-individual variability of 
lipids to clinical outcomes, describe its relation to lipid-lowering treatment, and briefly summarize which 
genetic variants have previously been found to contribute to increased lipid variability. In addition, we 
present data from the first genome-wide association study (GWAS) on visit-to-visit variability of low-
density lipoprotein cholesterol (LDL-C) and high-density lipoprotein cholesterol (HDL-C) levels, using 
data from the PROspective Study of Pravastatin in the Elderly at Risk for vascular disease (PROSPER). 
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Clinical significance  
In 1960 an interesting collection of observations was published by Groover et al., who examined 177 
military personnel over 5 years. Comparing cholesterol fluctuations over this period, it appeared that the 
group of individuals who had developed clinical manifestations of coronary artery disease had greater 
fluctuations in the preceding years (though no formal statistical testing was performed).9 It wasn’t until 34 
years later that researchers from the Framingham study reported that greater long-term intra-individual 
variability in total cholesterol (TC) associates with all-cause mortality over a 24-year period in men, and 
with cardiovascular and coronary disease incidence and mortality in both sexes.10  
Only recently has an interest in the clinical impact of visit-to-visit variability of lipids re-emerged, with a 
number of studies showing that various metrics of higher variability also associate with clinical outcomes 
over shorter periods of follow-up (Table 1). Of these, five studies have reported that higher intra-
individual lipid variability is predictive of higher occurrence of adverse cardiovascular events. First, 
researchers from the Treating to New Targets (TNT) study found that variability of LDL-C is a predictor 
of cardiovascular events and mortality, independent of statin treatment, average LDL-C levels, and 
medication adherence as determined through pill count in individuals with stable coronary artery 
disease.11 These findings were recently replicated for measures of variability in HDL-C and triglycerides 
in the same population, additionally showing evidence that both LDL-C and triglyceride variability 
associate with incident diabetes.12 Similar findings between LDL-C variability and vascular events and 
all-cause mortality were shown in post-hoc analyses of the Incremental Decrease in End Points Through 
Aggressive Lipid-Lowering (IDEAL) trial of 8,658 patients with previous MI.13 In addition, Boey et al. 
observed that variability of LDL-C and HDL-C levels associated with 5-year occurrence of major adverse 
cardiac events after surviving ST-segment elevation myocardial infarction.14 Lastly, a recent large-scale 
investigation of over 3.5 million individuals from the Korean National Health Insurance System (NHIS) 
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cohort without a history of MI and stroke showed that higher TC variability linearly associated with 
greater incidence of MI, stroke and all-cause mortality.15 
Visit-to-visit variability of lipids has also been demonstrated to associate with other outcomes. Chang et 
al. found that fluctuations of HDL-C, but not LDL-C, associate with a higher risk of diabetic nephropathy 
progression in type 2 diabetes patients.16 Both LDL-C and HDL-C variability have additionally been 
shown to associate with decline in glomerular filtration rate, but not with incidence of albuminuria.17 
Findings from the Korean NIHS also suggest that lipid variability is related to change in kidney function, 
as analyses in almost 8.5 million individuals showed that increasing TC variability associated with 
progression to end-stage renal disease.18 Furthermore, higher variability of LDL-C was shown to cross-
sectionally associate with lower cognitive test performance in four cognitive domains, lower cerebral 
blood flow, and greater white matter hyperintensity volume, in older individuals at high risk for vascular 
disease, independent of average LDL-C levels and statin treatment.19 In addition, relatively smaller 
studies have shown cross-sectional associations between higher LDL-C variability and obstructive sleep 
apnea20 and maximum carotid intima-media thickness.21  
Several hypotheses have been put forward to explain these observational findings. On the one hand, lipid 
variability might simply be a risk marker for distinct pathological processes leading to adverse outcomes. 
These include (sub)clinical disease (e.g. inflammation, cancer, kidney or liver disease), but also use of, or 
non-adherence to, various types of medication.22 If so, interventions specifically aimed at reducing 
variability are not likely to be effective. On the other hand, lipid variability might represent a novel 
modifiable risk factor. In the past, intermittent high-fat diets have been used to induce atherosclerotic 
lesions in animals.23, 24 Moreover, it has recently been shown that lipid lowering treatment in both animal 
models and humans may lead to changes of the cholesterol content of plaques,25, 26 which may have 
consequences for plaque stability.27, 28 These studies provide circumstantial evidence that fluctuations in 
lipid levels could also causally lead to a higher occurrence of adverse events.  
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Current knowledge on lipid variability has important limitations. As recently argued for research on visit-
to-visit variability of BP,29 standardized definitions should be developed to facilitate comparisons across 
studies and assess whether reduction of variability will improve outcomes. Much of the evidence in 
favour of clinical significance of lipid variability stems from post-hoc analysis of trials, or from research 
with participants at high risk for vascular disease. However, the recent studies performed within the 
nationwide Korean NIHS suggest that these relationships might also hold for the general population, and 
may even be more pronounced within low-risk groups (e.g. younger age, or in absence of comorbidities 
such as obesity and diabetes).15, 18 To date, all studies have solely examined mid- to long-term lipid 
variability (i.e. months to years). While these studies have consistently shown that higher lipid variability 
associates with worse clinical outcomes, these investigations are largely incomparable due to the 
heterogeneity in chosen outcomes of interest and metrics of variability. More specifically, five different 
metrics have been used, though all are known to be susceptible to either trend effects or mean levels in a 
repeated measurements setting (Supplemental Table 1). Moreover, there exist large differences in source 
population and study design, fasting status, number and regularity of lipid measurements, and selection of 
covariates. In addition, we should acknowledge the likely presence of submission and publication bias, as 
evidenced by the substantial publication time gaps between the Air Force and Framingham articles and 
the more recent publications. It therefore remains to be seen whether lipid variability truly reflects a 
reproducible phenomenon, and whether more short-term (e.g. daily or weekly) fluctuations also hold 
promise for clinical risk assessment.  
Nonetheless, if it can be shown that appraisal of lipid variability could benefit risk assessment, this might 
influence ordering patterns of lipid levels in clinical practise. Researchers working with large-scale data 
from the Korean NHIS have recently shown that incorporating variability of different cardiovascular 
disease risk factors (including intra-individual variability of total cholesterol) substantially improved 
cardiovascular risk predictability compared with single measurement values or taking the average of 
repeated measurements30, though this was not examined separately for lipid variability. These findings are 
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in line with a previous simulation study showing that blood pressure and cholesterol variability may lead 
to substantial misclassification when cardiovascular risk assessment is based on single measurements31, 
and with increasing evidence that incorporating repeated measurements can improve cardiovascular risk 
prediction.32 Based on the current literature it is however not yet possible to make recommendations on 
the necessity of repeated lipid measurements in clinical practise either before or after starting lipid 
lowering treatment, beyond which is already viewed as necessary to overcome short-term fluctuations in 
lipid levels. 
 
Interplay with lipid-lowering treatment 
To date, few studies have systematically examined the effects of lipid-lowering treatment on intra-
individual variability of lipids. Commencement of statin treatment has been shown to lead to a minor 
decline in absolute values of visit-to-visit lipid variability in clinical trials,19 as measured by the intra-
individual standard deviation, with more intensive statin treatment leading to even more stable LDL-C 
levels.11, 13 While these dose-dependent results are not always seen in observational studies, this may be 
due to different prescription patterns.14 It is currently unknown whether drug-class effects exist, which 
have been described in research on visit-to-visit BP variability,33, 34 though a cross-over study in 26 
individuals with type 2 diabetes suggests that these might depend on the methods of measuring and 
calculating lipid profiles.35, 36 
Despite this absolute decrease, results (Table 2) from our PROSPER study suggest that statin therapy 
may also lead to a relative increase in lipid variability. This likely occurs because declines in average 
levels of lipids will generally be larger than declines in variability, which will influence relative metrics 
such as the coefficient of variation. However, it is expected that absolute declines will be of greater 
importance in clinical settings, offsetting any relative increase.  
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Another treatment-related factor contributing to intra-individual variability of lipids is non-adherence,37 
as has similarly been shown for antihypertensive medication and visit-to-visit variability of BP.38 While 
combined pharmacological treatment modalities may reduce adherence-associated variability,39 adjusting 
for non-adherence is often difficult due to the absence of reliable assessment methods,40, 41 which may 
limit which studies are best suited to investigate effects of visit-to-visit variability in absence of non-
adherence. However, studies which have performed analyses stratified by use of lipid-lowering agents 
have shown either highly comparable19 or more pronounced15, 18 associations between variability and 
clinical outcomes in individuals not using lipid-lowering medication. It is therefore unlikely that, at least 
in those studies, the findings can be explained solely by non-adherence. Dosing schedules can also 
influence variability. While high-dose monthly dosing of PCSK9-inhibitors are known to produce 
substantial fluctuations of LDL levels in between injections,42, 43 there exists tentative trial evidence that 
adverse neurocognitive events may be more prevalent, independent of on-treatment lipid levels.44 It will 
therefore be of interest for PCSK9-trials to examine the possible influence of lipid variability on cognitive 
test performance in greater detail. 
 
Genetic basis of visit-to-visit variability of lipids 
While over 157 loci associated with blood lipid levels have been identified and annotated through large-
scale efforts,45 little is known about the genetic predisposition for intra-individual variability of lipids. 
The same applies to variability of other physiological measures. For example, to date just one GWAS has 
been published on visit-to-visit variability of BP,46 which many consider the poster child of intra-
individual variability.  
Previously, Pereira et al. assessed the association between 11 genetic polymorphisms involved in lipid 
metabolism and intra-individual variability of total cholesterol and HDL-C in up to 458 men and women 
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from 27 feeding or supplement trials designed to change serum cholesterol.47 The authors found evidence 
that two polymorphisms may increase the variability of total cholesterol (ApoA4 -347 (0.015 mmol/l 
higher geometric mean of the intra-individual standard deviations for genotype 12/22 versus genotype 11, 
p=0.02); MTP -493 (0.017 mmol/l higher for genotype 11 versus genotype 12/22, p=0.004)). In a study of 
117 men with peripheral arterial disease, it was reported that those heterozygous for the ApoB EcoRI 
polymorphism had higher within-individual variation of total serum cholesterol concentration over a 
period of 5-10 years using annual lipid measurements.48 Furthermore, Porkka et al. examined the 
influence of selected genetic markers on long-term variability of serum lipids in up to 320 subjects aged 
3-18 years at baseline over 3-year intervals during a 6-year follow-up period.49 They found that ApoB 
Xbal genotypes significantly influenced variability of TC and LDL-C levels in both sexes, and variability 
of triglycerides in males only. Moreover, ApoAI/CIII genotype influenced variability of TC and LDL-C 
levels but again, only in males. Finally, by comparing within-pair differences in monozygotic twins, 
possible ‘variability gene effects’ on lipid levels of genes in the Kidd blood group locus and of the TaqIB 
polymorphism in the CETP gene have been demonstrated by Berg and colleagues.50, 51 
As no other studies have examined whether commonly occurring genetic variants are of importance to 
visit-to-visit variability of lipids, we undertook an explorative genome-wide association study on intra-
individual variability of LDL-C and HDL-C, as fluctuations in specifically these two lipid traits have 
recently been shown to associate with clinical outcomes.  
 
GWAS 
We included 2,530 individuals from the placebo-arm of the PHArmacogenetic study of Statin in the 
Elderly at risk (PHASE).52,53 Genotyping was conducted using Illumina 660-Quad beadchips and 
10 
 
imputation with MACH imputation software based on the Hapmap built II release 23. We excluded 
variants with a minor allele frequency below 1%, and those with an imputation quality below 0.3. 
Lipid levels were assessed after an overnight fast. LDL-C was directly measured, and visit-to-visit 
variability of both LDL-C and HDL-C was defined as the intra-individual standard deviation over each 
individual’s lipid measurements at 3, 6, 12, 24, and 36 months after randomisation.  
The association analyses were conducted using PROBABEL software (http://www.genabel.org/). For both 
LDL-C and HDL-C variability, an additive linear regression model was used. Given the negligible 
difference in absolute values of visit-to-visit variability between the two trial arms, we did not undertake 
genome-wide association analyses on the interaction terms with statin treatment. However, as non-
adherence to pravastatin might influence the degree of visit-to-visit lipid variability, the analyses 
presented here were conducted solely in the placebo group. All analyses were adjusted for age, gender, 
principal components of ancestry (n=4), and mean intra-individual lipid level during follow-up. The p-
value threshold for genome-wide significance was set at 5x10-8.  
Known host genes for variants of note found in the GWAS were located via the SCAN database 
(http://www.scandb.org/).54 Furthermore, we searched Phenoscanner 
(http://www.phenoscanner.medschl.cam.ac.uk),55 a curated database holding publicly available results from 
large-scale GWAS, for evidence of plausible mechanistic pathways for these three variants. In addition, 
we examined our GWAS results for the lead SNPs for loci previously found to associate with either LDL-
C or HDL-C levels at a genome-wide significant level in the largest lipid GWAS to date.45 As some lead 
SNPs were associated with both traits this list comprised 124 different lead SNPs. To account for multiple 
testing, the p-value threshold for statistical significance was set at 0.0002 (i.e. 0.05/248 tests). 
 
Results 
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We did not observe any genome-wide significant associations for additive effects on lipid variability 
(Figure 1). However, we did detect two suggestive (p<1x10-6) signals for LDL-C variability (KIAA0391 
and Amiloride-sensitive cation channel 1 neuronal (ACCN1)) and one for HDL-C variability (Dickkopf 
WNT Signaling Pathway Inhibitor 3 (DKK3)), as shown in Table 3. Q-Q plots did not reveal evidence of 
systematic bias (Supplementary Figure).  
In order to examine possible mechanistic pathways leading to lipid variability, we queried the three 
suggestive lead SNPs shown in Table 3 in the Phenoscanner database. However, with the exception of 
nominal associations with body-mass index and height (p-values between 0.05 and 0.001), no traits were 
shared by multiple variants (data not shown). 
Finally, as shown in Supplemental Table 2 and 3, no previously reported lead SNPs for loci associated 
with either LDL-C or HDL-C levels attained statistical significance after correction for multiple testing. 
 
Discussion 
In this narrative review we have presented the literature on visit-to-visit lipid variability to date. While the 
exact role of lipid lowering treatment remains to be elucidated, it is evident that the substantial clinical 
and methodological heterogeneity among studies impedes drawing strong conclusions regarding possible 
clinical significance. Furthermore, our current genome-wide association results suggest that most genetic 
variants, including those that influence mean LDL-C or HDL-C levels, are not associated with intra-
individual variability of lipids, or that their effects are too small to detect with our current sample size. 
Replication studies will therefore be necessary to determine whether these explorative findings reflect 
true associations or merely statistical noise. Given the negligible difference in absolute values of lipid 
variability between the two PROSPER trial arms, it appears unlikely or at least doubtful that clinically 
relevant pharmacogenetic-guided interventions will be based on common genetic variants.  
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The major limitations of our association analysis were the relatively small sample size, though not 
dissimilar to the sole GWAS study on visit-to-visit variability of BP, and the inclusion of exclusively 
European-descent participants. Future studies on (pharmaco)genetic effects on intra-individual lipid 
variability should carefully consider issues of non-adherence. In addition, the influence of number of 
visits, the effect of duration of time between measurements, and the proximity of lipid measurements to 
drug administration may be important to consider.47, 56, 57  
It should further be noted that intra-individual lipid variability will presumably vary within and among 
populations due to varying genetic and environmental factors, which could limit the generalizability of 
any given study.47 For example, it is likely that genetic factors of importance will differ between younger 
and older populations, as age- or clinical disease-related disturbances to homeostatic mechanisms will be 
of little significance to younger populations. This is supported by research on the heritability of intra-
individual BP variability, as researchers from the Twins UK cohort found that environmental factors were 
responsible for over 80% of the variance in variability in older age groups, versus over 50% for twin pairs 
younger than 51 years.58 However, given that age-related loss of physiological homeostasis would 
presumably lead to greater overall intrinsic variability,59 there might exist genetic variants of importance 
to visit-to-visit variability of multiple physiological measures in older populations.  
Future studies could focus on overall genetic predisposition to lipid levels in greater detail, by examining 
loci previously found to associate with lipid metabolism,45 as those individuals genetically predisposed to 
certain lipid levels might be less likely to vary from visit-to-visit. In addition, factoring in lipid-lowering 
treatment may enhance power for the detection of genes of importance to intra-individual variability of 
lipids, especially if genetic loci have a differential effect conditional on the treatment. Gene-environment-
wide interaction studies (GEWIS) using a joint meta-analysis (JMA) approach may therefore provide 
further insight into the (pharmaco)genetic background of visit-to-visit variability of lipids.60 While these 
methods are promising, there remains ample room for the development of methodology and statistical 
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software packages to detect genetic loci affecting visit-to-visit variability, which account for phenotypic 
variability across individuals.61  
In summary, while visit-to-visit variability could be a novel prognostic marker for clinical practice, 
additional efforts are needed to harmonise phenotype definitions across different studies, and replication 
studies are required to definitively assess the possible importance of (pharmaco)genetic factors.  
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Figure legend 
Figure 1. Genome-wide Manhattan plots for visit-to-visit variability of low-density lipoprotein 
cholesterol (LDL-C) and high-density lipoprotein cholesterol (HDL-C), as measured by the intra-
individual standard deviation, in the placebo group (n=2,530) of the Prospective Study of Pravastatin in 
the Elderly at Risk (PROSPER). Individual –log10 p-values are plotted against their genomic position. 
Adjusted for age, gender, mean intra-individual lipid level during follow-up, and principal components of 
ancestry (n=4).  
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Table 1. Chronologically listed studies which have reported on associations between visit-to-visit lipid variability and (sub)clinical outcomes 
Clinically overt cardiovascular disease 
First author 
(year) 
Study population/design Lipid traits Variability 
metric(s) 
Number of, and time between, 
measurements 
Model covariates Main results 
Groover9 
(1960) 
177 men aged 40 to 60 years, comparison 
between individuals who did (n=16) and did 
not develop CAD, cross-sectional analysis 
TC (non-
fasted) 
% difference 
between 
highest and 
average of 
measurement(s) 
≥6 yearly measurements for 5 
consecutive years, time intervals 
unspecified 
None (no formal statistical 
testing) 
Greater deviations from 5-year average within CAD 
group 
       
Kreger10 
(1994) 
1,505 women and 1,407 men aged 30 to 62 
years, population-based cohort, follow-up of 
24 years 
TC (non-
fasted) 
RMSE 6 biennial measurements Age, average slope of TC, 
mean TC 
Higher variability associated with all-cause 
mortality and cardiovascular and coronary 
incidence and mortality in both sexes 
       
Bangalore11 
(2015)# 
9,572 patients aged 35 to 75 years with 
known CAD, post-hoc analysis from RCT 
comparing atorvastatin 80 versus 10 mg/day, 
median follow-up of 4.9 years 
LDL-C 
(fasted) 
s.d., ASV, CV, 
cVIM 
At week 12, at 12 months, 
thereafter annual, minimum of 2 
post-baseline measurements 
Age, adherence (pill count), 
mean LDL-C, treatment arm 
Higher variability associated with higher incidence 
of any coronary or cardiovascular event, all-cause 
mortality, MI, and stroke 
       
Boey14 
(2016) 
130 patients aged 54.1 ± 9.3 years with ST-
segment elevation myocardial infarction and 
surviving to discharge, mean follow-up of 
62.4 ± 30.5 months 
LDL-C, 
HDL-C (non-
fasted) 
s.d., CV, cVIM 
9.1 ± 4.5 LDL-C measurements,  
9.3 ± 4.5 HDL-C measurements, 
minimum of 3 from two months 
after discharge, with variable 
measurement schedules 
Mean lipid levels, diabetes 
mellitus 
Higher variability in both LDL-C and HDL-C 
associated with higher risk of major adverse cardiac 
event (death, MI, stroke, unplanned 
revascularization, heart failure admission) 
       
Bangalore13 
(2017) 
8,658 patients aged 62 ± 9.5 years with 
previous MI, post-hoc analysis from RCT 
comparing atorvastatin 80 mg/day versus 
simvastatin 20 mg/day, median follow-up 4.8 
years 
LDL-C 
(fasted) 
s.d., ASV, CV, 
cVIM 
At week 12, 24, year 1, 
thereafter yearly 
Demographics, treatment arm, 
cardiovascular comorbidities, 
mean LDL-C 
Higher variability associated with risk of any 
coronary or cardiovascular event, all-cause 
mortality, and MI 
       
Kim15 
(2017)* 
3,656,648 individuals aged 44.9 ±12.6 years 
without history of MI and stroke, population-
based cohort, median follow-up of 8.3 years 
TC (fasted) s.d., CV, VIM 
3-6 measurements during 6 
years (4.2±1.2), time intervals 
unspecified 
Demographics, cardiovascular 
comorbidities, baseline and/or 
mean TC, lipid-lowering 
treatment 
Higher variability linearly associated with 
incidence of MI, stroke and all-cause mortality 
       
Waters12 
(2017)# 
9,572 patients aged 35 to 75 years with 
known CAD, post-hoc analysis from RCT 
comparing atorvastatin 80 versus 10 mg/day, 
median follow-up of 4.9 years 
LDL-C, 
HDL-C, TG 
(fasted) 
s.d., ASV, CV, 
cVIM 
At week 12, at 12 months, 
thereafter annual, minimum of 2 
post-baseline measurements 
Demographics, cardiovascular 
comorbidities, mean lipid 
levels, treatment arm, change 
in lipid levels 
Higher variability in each lipid trait associated with 
incidence of coronary and cardiovascular events. In 
addition, LDL-C and TG variability associated with 
incident diabetes. 
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Table 1 continued. 
Other outcomes 
First author 
(year) 
Study population/design Lipid traits Variability 
metric(s) 
Number of, and time between, 
measurements 
Model covariates Main results 
Chang16 
(2013) 
864 type 2 diabetic patients aged 62.7 ± 11.8 
years, mean follow-up of 3.8 years 
TC, LDL-C, 
HDL-C, TG 
(fasted) 
s.d. 
8.5 ± 1.5 measurements, 
measured either quarterly or 
every 6 months 
Demographics, smoking, 
disease duration, kidney 
function, ACEI/ARB, lipid-
lowering treatment 
Higher HDL-C variability associated with higher 
risk of diabetic nephropathy progression 
       
Smit19 
(2016) 
4,428 patients aged 70 to 82 years at high risk 
of vascular disease, post-hoc analysis from 
placebo-controlled RCT of pravastatin 40 
mg/day, with MRI substudy of 535 
participants, cross-sectional analyses stratified 
by treatment arm 
LDL-C 
(fasted) 
s.d. 
4 post-baseline measurements at  
months 3, 6, 12, 24  
(92% with all 4) 
Demographics, cardiovascular 
comorbidities, mean LDL-C 
Higher variability associated with worse cognitive 
performance at month 30 for selective attention, 
processing speed, immediate and delayed recall, 
and with lower cerebral blood flow and greater 
white matter hyperintensity load at end of study, in 
both treatment arms 
       
Ng20 
(2017) 
190 patients aged 54.0 ± 8.8 years with 
known CAD, cohort followed up after 
overnight sleep study, cross-sectional 
analyses  
LDL-C 
(fasted) 
cVIM 
8.1 ± 4.2 (minimum of 3) 
measurements during 53.2 ± 
25.3 months, time intervals 
unspecified 
Diabetes mellitus, 
hyperlipidemia 
Higher scores on apnea-hypopnea index associated 
with greater visit-to-visit variability 
       
Takenouchi21 
(2017) 
162 type 2 diabetic patients aged 62 ± 10 
years, cross-sectional analyses 
LDL-C 
(fasted) 
s.d. 
94% had 6 measurements 
measured during 12 month 
period, time intervals 
unspecified 
Age, sex Higher variability associated with maximum carotid 
intima-media thickness 
       
Ceriello17 
(2017) 
Type 2 diabetes patients, 2 cohorts: 4,231 
with median age of 67.4 (IQR: 60.3-73.4) and 
normoalbuminuria, 7,560 aged 65.0 (58.5-
71.3) with eGFR ≥ 60 mL/min/1.73 m2,  
median follow-up 3.4 years (range 1.7-4.2)  
TC, LDL-C, 
HDL-C, TG 
(fasting status 
unspecified) 
s.d. ≥5 measurements over 3 years, 
time intervals unspecified 
Demographics, baseline lipid 
levels/blood pressure/kidney 
function, glucose- and lipid-
lowering treatment, 
ACEI/ARB, duration of 
diabetes 
No associations with incident albuminuria. 
However, higher variability in LDL-C and HDL-C 
associated with increased risk for decline in eGFR 
below 60 mL/min/1.73 m2 
       
Kim18 
(2017)* 
8,493,277 individuals aged 48.5 ± 13.8 years 
and free from ESRD, population-based 
cohort, median follow-up 6.1 years 
TC (fasted) s.d., CV, VIM 
3-5 measurements over 6 years  
(3.5 ± 0.8), time intervals 
unspecified 
Demographics, cardiovascular 
comorbidities, baseline and/or 
mean TC, lipid-lowering 
treatment, baseline kidney 
function 
Graded association between higher variability with 
incident ESRD 
#/*: complete/partial overlap in study populations. RCT denotes randomized clinical trial; CAD, coronary artery disease; MI, myocardial infarction; eGFR, estimated glomerular filtration rate; ESRD, end-stage renal disease; 
TC, total cholesterol; LDL-C, low-density lipoprotein cholesterol; HDL-C, high-density lipoprotein cholesterol; TG, triglycerides; RSME, square root of mean squared error ; s.d., standard deviation; ASV, average successive 
variability; CV, coefficient of variation; (c)VIM, (corrected) variation independent of mean; ACEI/ARB, angiotensin converting enzyme inhibitor or angiotensin receptor blocker. 
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Table 2. Demographic characteristics and lipid parameters for the PROSPER study 
 Placebo  
(n=2,530) 
Pravastatin 
(n=2,504) 
p-value 
Age at randomisation 75.31 ± 3.35 75.33 ± 3.35 - 
Females (%) 1309 (51.7) 1300 (51.9) - 
Lipid parameters at baseline (mmol/L)    
   LDL-C 3.79 ± 0.78 3.80 ± 0.81 - 
   HDL-C 1.28 ± 0.34 1.29 ± 0.36 - 
    
Lipid parameters during follow-up (mmol/L)*    
   No. of measurements 4.39 ± 0.82 4.39 ± 0.81 0.98 
   Average LDL-C 3.70 ± 0.76 2.56 ± 0.65 <0.001 
   LDL-C variability (standard deviation) 0.33 ± 0.21 0.32 ± 0.24 0.02 
   LDL-C variability (coefficient of variation) 0.09 ± 0.06 0.13 ± 0.13 <0.001 
   Average HDL-C 1.33 ± 0.36 1.40 ± 0.38 <0.001 
   HDL-C variability (standard deviation) 0.12 ± 0.08 0.13 ± 0.08 0.001 
   HDL-C variability (coefficient of variation) 0.09 ± 0.05 0.09 ± 0.05 0.53 
Unless otherwise specified, data are presented as mean ± standard deviation. P-values calculated 
using Student t-test and Pearson’s chi-square test when appropriate. 
LDL-C denotes low-density lipoprotein cholesterol; HDL-C, high-density lipoprotein cholesterol 
* calculated per-individual, over months 3 to 36  
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Table 3. Genetic variants independently associated with lipid variability at p < 1x10-6 (n=2,530) 
Trait Lead SNP Chr. Position Gene* 
Coding allele 
(CA) 
Noncoding 
allele 
Freq. CA Beta † s.e. p-value 
LDL-C variability rs2295463 14 34806024 KIAA0391 C T 0.98 -0.115 0.022 1.3 x 10-7 
 rs11867369 17 29243349 ACCN1 C T 0.09 0.050 0.010 3.9 x 10-7 
           
HDL-C variability rs4757730 11 11971832 DKK3 G T 0.90 0.016 0.003 3.0 x 10-7 
Chr., chromosome; LDL-C, low-density lipoprotein cholesterol; HDL-C, high-density lipoprotein cholesterol 
* As reported by the SCAN database (available at http://www.scandb.org). 
† Beta for per-allele additive effect on lipid variability (intra-individual standard deviation, mmol/L), adjusted for age, sex, mean intra-individual lipid level, and principal components of 
ancestry (n=4).  
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Supplemental Table 1. Metrics of lipid visit-to-visit variability used in the literature  
Measure Formula Properties 
Square root of 
mean squared error 
(RSME) 
�
∑ (𝑥𝑥𝑖𝑖 − 𝑥𝑥�𝑖𝑖)2𝑛𝑛𝑖𝑖=1
𝑛𝑛 − 2  
With 𝑥𝑥�𝑖𝑖 obtained from fitting x 
against time 
Takes (assumed to be linear) 
trend of repeated measurements 
into account, but is susceptible 
to differences in mean follow-
up levels 
Standard deviation 
(s.d) 
�
∑ (𝑥𝑥𝑖𝑖 − ?̅?𝑥)2𝑛𝑛𝑖𝑖=1(𝑛𝑛 − 1)  
Dependent on mean follow-up 
levels, and susceptible to trend 
across measurements 
Coefficient of 
variation (CV) 
𝑠𝑠.𝑑𝑑.
?̅?𝑥
 
Largely independent of mean 
follow-up levels, but 
susceptible to trend effects 
Average 
successive 
variability (ASV) 
∑ |𝑥𝑥𝑖𝑖+1 − 𝑥𝑥𝑖𝑖|𝑛𝑛−1𝑖𝑖=1
𝑛𝑛 − 1  
Largely independent of trend 
effects, but susceptible to 
differences in mean follow-up 
levels 
Corrected variation 
independent of 
mean (cVIM) 
 
𝑉𝑉𝑉𝑉𝑉𝑉 = 𝑠𝑠.𝑑𝑑.
?̅?𝑥𝑏𝑏𝑏𝑏𝑏𝑏𝑏𝑏
 
With beta obtained from fitting s.d. 
on ?̅?𝑥, after natural log-
transformation. 
𝑐𝑐𝑉𝑉𝑉𝑉𝑉𝑉 = (𝑉𝑉𝑉𝑉𝑉𝑉 × 𝐶𝐶𝑉𝑉����)
𝑉𝑉𝑉𝑉𝑉𝑉
 
Independent of mean follow-up 
levels, but susceptible to trend 
effects 
 𝑥𝑥𝑖𝑖 denotes the i-th measurement of a set of n-measurements 
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Supplemental Figure. Q-Q plots for the two genome-wide association analyses. Corresponding λ’s: (A) 
0.995; (B) 1.002  
 
 
Supplemental Table 2. Lead SNPs for previously reported loci for LDL-C levels. 
SNP Chr. Locus LDL-C var. HDL-C var. 
rs10102164 8 SOX17 0.03 0.66 
rs10128711 11 SPTY2D1 0.56 0.56 
rs10401969 19 CILP2 0.35 0.24 
rs10490626 2 INSIG2 0.66 0.29 
rs11065987 12 BRAP 0.51 0.89 
rs11136341 8 PLEC1 0.92 0.55 
rs11220462 11 ST3GAL4 0.9 0.21 
rs11563251 2 UGT1A1 0.11 0.47 
rs1169288 12 HNF1A 0.07 0.85 
rs12027135 1 LDLRAP1 0.61 0.56 
rs1250229 2 FN1 0.11 0.5 
rs12670798 7 DNAH11 0.62 0.73 
rs12748152 1 PIGV-NR0B2 0.12 0.44 
rs12916 5 HMGCR 0.75 0.26 
rs1367117 2 APOB 0.89 0.54 
rs1564348 6 LPA 0.43 0.19 
rs17404153 3 ACAD11 0.54 0.27 
rs174546 11 FADS1-2-3 0.25 0.55 
rs1800562 6 HFE 0.55 0.49 
rs1800961 20 HNF4A 0.03 0.57 
rs1883025 9 ABCA1 0.39 0.78 
rs2000999 16 HPR 0.76 0.31 
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rs2030746 2 LOC84931 0.85 0.26 
rs2072183 7 NPC1L1 0.68 0.77 
rs2131925 1 ANGPTL3 0.13 0.57 
rs2255141 10 GPAM 0.42 0.38 
rs2328223 20 SNX5 0.69 0.74 
rs2479409 1 PCSK9 0.21 0.34 
rs2642442 1 MOSC1 0.5 0.17 
rs267733 1 ANXA9-CERS2 0.51 0.62 
rs2710642 2 EHBP1 0.85 0.46 
rs2902940 20 MAFB 0.28 0.3 
rs2954029 8 TRIB1 0.05 0.72 
rs314253 17 DLG4 0.94 0.43 
rs3177928 6 HLA 0.05 0.63 
rs364585 20 SPTLC3 0.16 0.72 
rs3757354 6 MYLIP 0.42 0.93 
rs3764261 16 CETP 0.05 0.48 
rs3780181 9 VLDLR 0.65 0.06 
rs4253776 22 PPARA 0.7 0.48 
rs4299376 2 ABCG5/8 0.18 0.02 
rs4420638 19 APOE 0.79 0.97 
rs4530754 5 CSNK1G3 0.5 0.92 
rs4722551 7 MIR148A 0.83 0.72 
rs492602 19 FLJ36070 0.68 0.28 
rs4942486 13 BRCA2 0.85 0.17 
rs514230 1 IRF2BP2 0.16 0.1 
rs5763662 22 MTMR3 0.41 0.92 
rs6029526 20 TOP1 0.93 0.92 
rs629301 1 SORT1 0.26 0.78 
rs6511720 19 LDLR 0.38 0.61 
rs6818397 4 LRPAP1 0.2 0.87 
rs6882076 5 TIMD4 0.19 0.55 
rs7570971 2 RAB3GAP1 0.34 0.65 
rs7640978 3 CMTM6 0.42 0.57 
rs8017377 14 NYNRIN 0.39 0.43 
rs964184 11 APOA1 0.003 0.37 
rs9987289 8 PPP1R3B 0.06 0.47 
Data are presented as p-values for additive effects on visit-to-visit lipid variability as measured by the intra-
individual standard deviation. Lead SNPs as reported by Willer CJ, Schmidt EM, Sengupta S, et al. Discovery 
and refinement of loci associated with lipid levels. Nat Genet. 2013;45:1274-1283. 
 
 
Supplemental Table 3. Lead SNPs for previously reported loci for HDL-C levels. 
SNP Chr. Locus LDL-C var. HDL-C var. 
rs10019888 4 C4orf52 0.19 0.2 
rs11065987 12 BRAP 0.51 0.89 
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rs1121980 16 FTO 0.29 0.51 
rs11246602 11 OR4C46 0.69 0.53 
rs11613352 12 LRP1 0.48 0.43 
rs11869286 17 STARD3 0.56 0.77 
rs12145743 1 HDGF-PMVK 0.99 0.97 
rs12328675 2 COBLL1 0.13 0.76 
rs12678919 8 LPL 0.31 0.17 
rs12748152 1 PIGV-NR0B2 0.12 0.44 
rs12801636 11 KAT5 0.07 0.19 
rs12967135 18 MC4R 0.41 0.27 
rs13076253 3 ACAD11 0.98 0.23 
rs13107325 4 SLC39A8 0.54 0.01 
rs13326165 3 STAB1 0.84 0.25 
rs1367117 2 APOB 0.89 0.54 
rs1532085 15 LIPC 0.14 0.78 
rs1689800 1 ZNF648 0.04 0.84 
rs16942887 16 LCAT 0.15 0.56 
rs17145738 7 MLXIPL 0.65 0.78 
rs17173637 7 TMEM176A 0.1 0.34 
rs174546 11 FADS1-2-3 0.25 0.55 
rs17695224 19 HAS1 0.55 0.9 
rs1800961 20 HNF4A 0.03 0.57 
rs181362 22 UBE2L3 0.33 0.63 
rs1883025 9 ABCA1 0.39 0.78 
rs1936800 6 RSPO3 0.42 0.86 
rs2013208 3 RBM5 0.06 0.52 
rs2255141 10 GPAM 0.42 0.38 
rs2290547 3 SETD2 0.18 0.45 
rs2293889 8 TRPS1 0.62 0.61 
rs2412710 15 CAPN3 0.78 0.31 
rs2602836 4 ADH5 0.04 0.91 
rs2606736 3 ATG7 0.4 0.27 
rs2652834 15 LACTB 0.62 0.69 
rs2814982 6 C6orf106 0.89 0.22 
rs2923084 11 AMPD3 0.09 0.88 
rs2925979 16 CMIP 0.38 0.79 
rs2954029 8 TRIB1 0.05 0.72 
rs2972146 2 IRS1 0.59 0.05 
rs3136441 11 LRP4 0.24 0.22 
rs3764261 16 CETP 0.05 0.48 
rs3822072 4 FAM13A 0.46 0.58 
rs386000 19 LILRA3 0.72 0.12 
rs4129767 17 PGS1 0.52 0.35 
rs4142995 7 SNX13 0.25 0.87 
rs4148008 17 ABCA8 0.31 0.92 
rs4420638 19 APOE 0.79 0.97 
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rs442177 4 KLHL8 0.8 0.25 
rs4650994 1 ANGPTL1 0.69 0.27 
rs4660293 1 PABPC4 0.49 0.06 
rs4731702 7 KLF14 0.64 0.81 
rs4759375 12 SBNO1 0.02 0.61 
rs4765127 12 ZNF664 0.83 0.31 
rs4846914 1 GALNT2 0.13 0.003 
rs4917014 7 IKZF1 0.92 0.81 
rs4983559 14 ZBTB42-AKT1 0.63 0.41 
rs499974 11 MOGAT2-DGAT2 0.46 0.78 
rs581080 9 TTC39B 0.94 0.88 
rs605066 6 CITED2 0.45 0.27 
rs6065906 20 PLTP 0.73 0.57 
rs629301 1 SORT1 0.26 0.78 
rs6450176 5 ARL15 0.55 0.8 
rs645040 3 MSL2L1 0.65 0.95 
rs6805251 3 GSK3B 0.97 0.39 
rs702485 7 DAGLB 0.95 0.38 
rs7134375 12 PDE3A 0.6 0.59 
rs7134594 12 MVK 0.05 0.34 
rs7241918 18 LIPG 0.52 0.96 
rs7255436 19 ANGPTL4 0.83 0.55 
rs731839 19 PEPD 0.54 0.46 
rs737337 19 ANGPTL8 0.16 0.81 
rs7941030 11 UBASH3B 0.84 0.48 
rs838880 12 SCARB1 0.27 0.95 
rs964184 11 APOA1 0.003 0.37 
rs9686661 5 MAP3K1 0.37 0.78 
rs970548 10 MARCH8-ALOX5 0.54 0.49 
rs998584 6 VEGFA 0.42 0.52 
rs9987289 8 PPP1R3B 0.06 0.47 
Data are presented as p-values for additive effects on visit-to-visit lipid variability as measured by the intra-
individual standard deviation. Lead SNPs as reported by Willer CJ, Schmidt EM, Sengupta S, et al. Discovery 
and refinement of loci associated with lipid levels. Nat Genet. 2013;45:1274-1283. 
 
 
 
 
 
